TO/SB/21 (04-04)

			PTO/SB/21 (04-04)
OIPE	<u> </u>	Application Number	08/958,570
TRANSMITTAL		Filing Date	October 28, 1997
NOV 0 1 2004 SPORM		First Named Inventor	Gregory, Richard J.
(to be used for all compspondence after initial filing)		(ing) Art Unit	1636
(to be used for all compspondence after initial filling) Total Number of Pages in This Submission		Examiner Name	Guzo, David
RAPENT		Attorney Docket Number	016930-000921US
Total Number of	Pages in This Submission		010330-03032100
ENCLOSURES (Check all that apply)			
Fee Transmittal Form Fee Attached Amendment and Communication Under 37 CFR 1.821-1.825 After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application		Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Address Terminal Disclaimer Request for Refund CD, Number of CD(s) Remarks The Commissioner is au Account 20-1430.	to Technology Center (TC) Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please identify below): Return Postcard uthorized to charge any additional fees to Deposit
Response to Missing Parts under 37 CFR 1.52 or 1.53			•
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm or	Townsend and Townsend and Crew LLP		
Individual name	Chris J. Ullsperger Reg. No. 48,006		
Signature			
Date	October 27, 2004		
CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. Typed or printed name Judith Cotham			
Signature until (ti Cold	Date October 27, 2004

NOV 0 1 2004

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

<u>PATENT</u>

Attorney Docket No.: 016930-000921US

Client Ref. No.: 3005 Customer No.: 20350

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

On _____

TOWNSEND and TOWNSEND and CREW LAP

By:_

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

GREGORY et al.

Application No.: 08/958,570

Filed: October 28, 1997

For: RECOMBINANT ADENOVIRAL VECTOR AND METHODS OF USE

Confirmation No. 3556

Examiner:

Guzo, David

Art Unit:

1636

COMMUNICATION UNDER

<u>37 C.F.R. §§ 1.821-1.825</u>

<u>AND</u>

<u>AMENDMENT</u>

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Office Action, mailed August 27, 2004, Applicants submit that the computer-readable form in the instant application is identical with the Substitute Sequence Listing submitted for Application No. 08/328,673 on February 15, 2000. In accordance with 37 C.F.R. § 1.821(e), please use the last-filed computer-readable form submitted for Application No. 08/328,673 as the computer-readable form for the instant application. The information in

Appl. No. 08/958,570 Amdt. dated September 30, 2004 Reply to Office Action of August 27, 2004

the paper copy of the Substitute Sequence Listing enclosed herewith is identical to that which is in the computer readable form, as required under 37 C.F.R. § 1.821(f).

It is understood that the Patent and Trademark Office will make the necessary changes in application number and filing date for the computer-readable form that will be used for the instant application.

Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

Amendments to the Specification begin on page 3 of this paper.

Amendments to the Abstract begin on page 4 of this paper.

Remarks begin on page 4 of this paper.